1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Former Commissioners Push For Sharpless Nomination, Confirmation

 
• By Derrick Gingery

Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.

FDA acting Commissioner Ned Sharpless at Reagan-Udall Foundation for FDA. (1)
Norman Sharpless may only serve as acting FDA commissioner for 210 days unless he is nominated for the permanent position. • Source: File photo

With his time as acting US Food and Drug Administration commissioner running short, Norman Sharpless has received endorsements from multiple former agency leaders and several stakeholder groups to continue in the permanent position.

Four former commissioners, appointed under Republican and Democratic administrations, called for Sharpless to be nominated and confirmed as commissioner. In a 3 September 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.